Last reviewed · How we verify

NCT07527143

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

Not yet recruiting Last updated 14 April 2026
What this trial tests

trial testing Non-Interventional Study in Endometrial Carcinoma in 25 participants. Not yet recruiting.

Timeline
6 April 2026
Primary endpoint
6 April 2027
6 April 2027

Quick facts

Lead sponsorMayo Clinic
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment25
Start date6 April 2026
Primary completion6 April 2027
Estimated completion6 April 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

45 and older, female only, with Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Endometrial Carcinoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing